ChemInform Abstract: Green Light-Excitable Ce-Doped Nitridomagnesoaluminate Sr[Mg2Al2N4] Phosphor for White Light-Emitting Diodes.

ChemInform ◽  
2016 ◽  
Vol 47 (51) ◽  
Author(s):  
Ru-Shi Liu ◽  
et al.
Keyword(s):  
White Light ◽  
Light Emitting Diodes ◽  
Green Light ◽  
Light Emitting ◽  
White Light Emitting Diodes

scholarly journals Green Light Exposure Improves Pain and Quality of Life in Fibromyalgia Patients: A Preliminary One-Way Crossover Clinical Trial

Pain Medicine ◽  
2020 ◽  
Author(s):  
Laurent Martin ◽  
Frank Porreca ◽  
Elizabeth I Mata ◽  
Michelle Salloum ◽  
Vasudha Goel ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
White Light ◽  
Light Emitting Diodes ◽  
Green Light ◽  
Pain Clinic ◽  
Mcgill Pain Questionnaire ◽  
Light Emitting ◽  
White Light Emitting Diodes

Abstract Objective Fibromyalgia is a functional pain disorder in which patients suffer from widespread pain and poor quality of life. Fibromyalgia pain and its impact on quality of life are not effectively managed with current therapeutics. Previously, in a preclinical rat study, we demonstrated that exposure to green light-emitting diodes (GLED) for 8 hours/day for 5 days resulted in antinociception and reversal of thermal and mechanical hypersensitivity associated with models of injury-related pain. Given the safety of GLED and the ease of its use, our objective is to administer GLED as a potential therapy to patients with fibromyalgia. Design One-way crossover clinical trial. Setting United States. Method We enrolled 21 adult patients with fibromyalgia recruited from the University of Arizona chronic pain clinic who were initially exposed to white light-emitting diodes and then were crossed over to GLED for 1 to 2 hours daily for 10 weeks. Data were collected by using paper surveys. Results When patients were exposed to GLED, but not white light-emitting diodes, they reported a significant reduction in average pain intensity on the 10-point numeric pain scale. Secondary outcomes were assessed by using the EQ-5D-5L survey, Short-Form McGill Pain Questionnaire, and Fibromyalgia Impact Questionnaire and were also significantly improved in patients exposed to GLED. GLED therapy was not associated with any measured side effects in these patients. Conclusion Although the mechanism by which GLED elicits pain reduction is currently being studied, these results supporting its efficacy and safety merit a larger clinical trial.

scholarly journals Green Light-Excitable Ce-Doped Nitridomagnesoaluminate Sr[Mg2Al2N4] Phosphor for White Light-Emitting Diodes

2016 ◽  
Vol 28 (19) ◽  
pp. 6822-6825 ◽  
Author(s):  
Julius L. Leaño ◽  
Shin-Ying Lin ◽  
Agata Lazarowska ◽  
Sebastian Mahlik ◽  
Marek Grinberg ◽  
...  
Keyword(s):  
White Light ◽  
Light Emitting Diodes ◽  
Green Light ◽  
Light Emitting ◽  
White Light Emitting Diodes

scholarly journals Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial

Cephalalgia ◽  
2020 ◽  
pp. 033310242095671
Author(s):  
Laurent F Martin ◽  
Amol M Patwardhan ◽  
Sejal V Jain ◽  
Michelle M Salloum ◽  
Julia Freeman ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Migraine ◽  
White Light ◽  
Light Emitting Diodes ◽  
Green Light ◽  
Episodic Migraine ◽  
Secondary Outcome ◽  
Light Emitting ◽  
White Light Emitting Diodes

Background Pharmacological management of migraine can be ineffective for some patients. We previously demonstrated that exposure to green light resulted in antinociception and reversal of thermal and mechanical hypersensitivity in rodent pain models. Given the safety of green light emitting diodes, we evaluated green light as a potential therapy in patients with episodic or chronic migraine. Material and methods We recruited (29 total) patients, of whom seven had episodic migraine and 22 had chronic migraine. We used a one-way cross-over design consisting of exposure for 1–2 hours daily to white light emitting diodes for 10 weeks, followed by a 2-week washout period followed by exposure for 1–2 hours daily to green light emitting diodes for 10 weeks. Patients were allowed to continue current therapies and to initiate new treatments as directed by their physicians. Outcomes consisted of patient-reported surveys. The primary outcome measure was the number of headache days per month. Secondary outcome measures included patient-reported changes in the intensity and frequency of the headaches over a two-week period and other quality of life measures including ability to fall and stay asleep, and ability to perform work. Changes in pain medications were obtained to assess potential reduction. Results When seven episodic migraine and 22 chronic migraine patients were analyzed as separate cohorts, white light emitting diodes produced no significant change in headache days in either episodic migraine or chronic migraine patients. Combining data from the episodic migraine and chronic migraine groups showed that white light emitting diodes produced a small, but statistically significant reduction in headache days from (days ± SEM) 18.2 ± 1.8 to 16.5 ± 2.01 days. Green light emitting diodes resulted in a significant decrease in headache days from 7.9 ± 1.6 to 2.4 ± 1.1 and from 22.3 ± 1.2 to 9.4 ± 1.6 in episodic migraine and chronic migraine patients, respectively. While some improvement in secondary outcomes was observed with white light emitting diodes, more secondary outcomes with significantly greater magnitude including assessments of quality of life, Short-Form McGill Pain Questionnaire, Headache Impact Test-6, and Five-level version of the EuroQol five-dimensional survey without reported side effects were observed with green light emitting diodes. Conclusions regarding pain medications reduction with green light emitting diode exposure were not possible. No side effects of light therapy were reported. None of the patients in the study reported initiation of new therapies. Discussion Green light emitting diodes significantly reduced the number of headache days in people with episodic migraine or chronic migraine. Additionally, green light emitting diodes significantly improved multiple secondary outcome measures including quality of life and intensity and duration of the headache attacks. As no adverse events were reported, green light emitting diodes may provide a treatment option for those patients who prefer non-pharmacological therapies or may be considered in complementing other treatment strategies. Limitations of this study are the small number of patients evaluated. The positive data obtained support implementation of larger clinical trials to determine possible effects of green light emitting diode therapy. This study is registered with clinicaltrials.gov under NCT03677206.

Enhanced Cyan Emission and Optical Tuning of Ca 3 Ga 4 O 9 :Bi 3+ for High‐Quality Full‐Spectrum White Light‐Emitting Diodes

2020 ◽  
Vol 8 (22) ◽  
pp. 2001037 ◽  
Author(s):  
Dongjie Liu ◽  
Xiaohan Yun ◽  
Guogang Li ◽  
Peipei Dang ◽  
Maxim S. Molokeev ◽  
...  
Keyword(s):  
White Light ◽  
Light Emitting Diodes ◽  
High Quality ◽  
Full Spectrum ◽  
Light Emitting ◽  
White Light Emitting Diodes

Glass-ceramic composites for high-power white-light-emitting diodes

2021 ◽  
Author(s):  
Alessandro Longato ◽  
Sebastiano Picco ◽  
Lorenzo Moro ◽  
Matteo Buffolo ◽  
Carlo De Santi ◽  
...  
Keyword(s):  
White Light ◽  
High Power ◽  
Glass Ceramic ◽  
Light Emitting Diodes ◽  
Ceramic Composites ◽  
Light Emitting ◽  
White Light Emitting Diodes
Sign in / Sign up

Export Citation Format

Share Document